Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response

References

• Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–10. doi:10.1016/S1470-2045(07)70039-6.
   PubMed Web of Science ®Google Scholar
• Greer SE, Goodney PP, Sutton JE, Birkmeyer JD. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005;137(2):172–177. doi:10.1016/j.surg.2004.06.033.
   PubMed Web of Science ®Google Scholar
• Mariette C, Triboulet JP. Is preoperative chemoradiation effective in treatment of oesophageal carcinoma? Lancet Oncol. 2005;6(9):635–637. doi:10.1016/S1470-2045(05)70295-36.
   PubMed Web of Science ®Google Scholar
• Malaisrie SC, Untch B, Aranha GV, Mohideen N, Hantel A, Pickleman J. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution. Arch Surg. 2004;139(5):532–538; discussion 538–9. doi:10.1001/archsurg.139.5.532.
   PubMedGoogle Scholar
• Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O’Byrne K, Kennedy J, Murphy TJ. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2007;245(5):707–716. doi:10.1097/01.sla.0000254367.15810.38.
   PubMed Web of Science ®Google Scholar
• Zacherl J, Sendler A, Stein HJ, Ott K, Feith M, Jakesz R, Siewert JR, Fink U. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg. 2003;27(9):1067–1074. doi:10.1007/s00268-003-7063-z.
   PubMed Web of Science ®Google Scholar
• Brücher BL, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R, Dittler HJ, Molls M, Fink U, Siewert JR. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004;30(9):963–971. doi:10.1016/j.ejso.2004.06.008.
   PubMed Web of Science ®Google Scholar
• Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23(19):4330–4337. doi:10.1200/JCO.2005.05.017.
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al.; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084. doi:10.1056/NEJMoa1112088.
   PubMed Web of Science ®Google Scholar
• Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137–1146. doi:10.1172/JCI31405.
   PubMed Web of Science ®Google Scholar
• Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654–2666. doi:10.1056/NEJMoa051424.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. doi:10.1126/science.1129139.
   PubMed Web of Science ®Google Scholar
• Yang WF, Yu JM, Zuo WS, Wang SZ. Expression of CD80, CD86, TGF-beta1 and IL-10 mRNA in the esophageal carcinoma. Zhonghua Zhong Liu Za Zhi. 2006;28:762–765.
   PubMedGoogle Scholar
• Yang W, Zhang Y, Yu J, Li S. The low expression of CD80 correlated with the vascular endothelial growth factor in esophageal cancer tissue. Eur J Surg Oncol. 2010 May;36(5):501–506. doi:10.1016/j.ejso.2010.01.007.
   PubMed Web of Science ®Google Scholar
• Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, Uramoro H, et al. Differences in sensitivity to tumor-specific CTLs between primary and metastatic esophageal cancer cell lines derived from the same patient. Surg Today. 2012;42(3):272–279. doi:10.1007/s00595-011-0083-7.
   PubMed Web of Science ®Google Scholar
• Lu B, Chen L, Liu L, Zhu Y, Wu C, Jiang J, Zhang X. T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol Res. 2011;50(2–3):269–275. doi:10.1007/s12026-011-8227-9.
   PubMed Web of Science ®Google Scholar
• Wagener-Ryczek S, Schoemmel M, Kraemer M, Bruns C, Schroeder W, Zander T, Gebauer F, Alakus H, Merkelbach-Bruse S, Buettner R, et al. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma. Cancer Immunol Immunother. 2020 Jan 20;69(4):523–533. doi:10.1007/s00262-019-02475-w.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–148. doi:10.1016/j.immuni.2004.07.017.
   PubMed Web of Science ®Google Scholar
• Castoro C, Scarpa M, Cagol M, Alfieri R, Ruol A, Cavallin F, Michieletto S, Zanchettin G, Chiarion-Sileni V, Corti L, et al. Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary? J Gastrointest Surg. 2013;17(8):1375–1381. doi:10.1007/s11605-013-2269-3.
   PubMed Web of Science ®Google Scholar
• Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim S-B, Lee JH, Bhutani MS, Swisher SG, et al. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010 Nov 30;5(11):e15074. doi:10.1371/journal.pone.0015074.
   PubMed Web of Science ®Google Scholar
• Edge SB, Bryd DR, Compton CC, Fritz AG, Greene F, Trotti A. AJCC cancer staging manual. 7th ed. New York, NY: Springer-Verlag; 2010.
   Google Scholar
• Ruol A, Portale G, Castoro C, Merigliano S, Cavallin F, Battaglia G, Michieletto S, Ancona E. Management of esophageal cancer in patients aged over 80 years. Eur J Cardiothorac Surg. 2007;32(3):445–448. doi:10.1016/j.ejcts.2007.06.014.
   PubMed Web of Science ®Google Scholar
• Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–2686. doi:10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2016.
   Google Scholar
• Noordman BJ, de Bekker-grob EW, Coene PPLO, van der Harst E, Lagarde SM, Shapiro J, Wijnhoven BPL, van Lanschot JJB. Patients’ preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer. Br J Surg. 2018;105(12):1630–1638. doi:10.1002/bjs.10897.
   PubMed Web of Science ®Google Scholar
• Chen W, Li Y, Yuan D, Peng Y, Qin J. Practical value of identifying circulating tumor cells to evaluate esophageal squamous cell carcinoma staging and treatment efficacy. Thorac Cancer. 2018;9(8):956–966. doi:10.1111/1759-7714.12771.
   PubMed Web of Science ®Google Scholar
• Fang P, Musall BC, Son JB, Moreno AC, Hobbs BP, Carter BW, Fellman BM, Mawlawi O, Ma J, Lin SH. Multimodal imaging of pathologic response to chemoradiation in esophageal cancer. Int J Radiat Oncol Biol Phys. 2018;102(4):996–1001. pii: S0360-3016(18)30328-6. doi:10.1016/j.ijrobp.2018.02.029.
   PubMed Web of Science ®Google Scholar
• Fang P, Jiang W, Davuluri R, Xu C, Krishnan S, Mohan R, Koong AC, Hsu CC, Lin SH. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. Radiother Oncol. 2018;128(3):584–590. pii: S0167-8140(18)30117-8. doi:10.1016/j.radonc.2018.02.025.
   PubMed Web of Science ®Google Scholar
• Scarpa M, Fassan M, Kotsafti A, Realdon S, Dall’Olmo L, Morbin T, Cavallin F, Saadeh L, Cagol M, Alfieri R, et al. CD80 expression promotes immune surveillance in Barrett’s metaplasia. Oncoimmunology. 2019 Jul 23;8(10):e1636618. doi:10.1080/2162402X.2019.1636618.
   PubMed Web of Science ®Google Scholar
• Ma JL, Jin L, Li YD, He CC, Guo XJ, Liu R, Yang YY, Han SX. The intensity of radiotherapy-elicited immune response is associated with esophageal cancer clearance. J Immunol Res. 2014;2014:794249. doi:10.1155/2014/794249.
   PubMed Web of Science ®Google Scholar
• Kotsafti A, D’Incà R, Scarpa M, Fassan M, Angriman I, Mescoli C, Bortoli N, Brun P, Bardini R, Rugge M, et al. Weak cytotoxic T cells activation predicts low-grade dysplasia persistence in ulcerative colitis. Clin Transl Gastroenterol. 2019 Jul;10(7):e00061. doi:10.14309/ctg.0000000000000061.
   PubMedGoogle Scholar
• Borggreve AS, Mook S, Verheij M, Mul VEM, Bergman JJ, Bartels-Rutten A, Ter Beek LC, Beets-Tan RGH, Bennink RJ, van Berge Henegouwen MI, et al.; PRIDE study group. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study. BMC Cancer. 2018 Oct 20;18(1):1006. doi:10.1186/s12885-018-4892-6.
   PubMedGoogle Scholar
• Schumacher K, Haensch W, Röefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001 May 15;61(10):3932–3936.
   PubMed Web of Science ®Google Scholar
• Scarpa M, Kotsafti A, Fassan M, Scarpa M, Cavallin F, Nardi T, Pinto E, Alfieri R, Cagol M, Agostini M, et al. Immunonutrition before esophagectomy: impact on immune surveillance mechanisms. Tumour Biol. 2017;39(10):1010428317728683. doi:10.1177/1010428317728683.
   Google Scholar
• Huang J, Li L, Liu J, Yu J, Wu X, Xu Y, Ma M, Wang W, Zhang R. Altered expression of lysosomal associated membrane protein 1 in esophageal squamous cell carcinoma. Pathol Res Pract. 2017;213(8):938–942. doi:10.1016/j.prp.2017.05.008.
   PubMed Web of Science ®Google Scholar
• Semenkovich TR, Meyers BF. Surveillance versus esophagectomy in esophageal cancer patients with a clinical complete response after induction chemoradiation. Ann Transl Med. 2018;6(4):81. doi:10.21037/atm.2018.01.31.
   PubMed Web of Science ®Google Scholar
• Kavanagh ME, Conroy MJ, Clarke NE, Gilmartin NT, O’Sullivan KE, Feighery R, MacCarthy F, O’Toole D, Ravi N, Reynolds JV, et al. Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma. Cancer Lett. 2016;370(1):117–124. doi:10.1016/j.canlet.2015.10.019.
   PubMed Web of Science ®Google Scholar
• Ohkura Y, Shindoh J, Ueno M, Iizuka T, Udagawa H. Comparison of outcome of esophagectomy versus nonsurgical treatment for resectable esophageal cancer with clinical complete response to neoadjuvant therapy. Ann Surg Oncol. 2018 Mar 21;(8):2428–2433.
   Web of Science ®Google Scholar
• Huhta H, Helminen O, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett’s esophagus, dysplasia and adenocarcinoma. Oncotarget. 2016;7(17):23658–23667. doi:10.18632/oncotarget.8151.
   PubMedGoogle Scholar
• Verbeek RE, Siersema PD, Ten Kate FJ, Fluiter K, Souza RF, Vleggaar FP, Bus P, van Baal JW. Toll-like receptor 4 activation in Barrett’s esophagus results in a strong increase in COX-2 expression. J Gastroenterol. 2014;49(7):1121–1134. doi:10.1007/s00535-013-0862-6.
   PubMed Web of Science ®Google Scholar
• Mariette C, Piessen G, Lamblin A, Mirabel X, Adenis A, Triboulet JP. Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma. Br J Surg. 2006;93(9):1077–1083. doi:10.1002/bjs.5358.
   PubMed Web of Science ®Google Scholar